Genetics in MedicineGenetic & Genomic MedicinePeer-reviewed journal article
Impact of genetic counselling strategy on diagnostic yield and workload for genome sequencing-based tumour diagnostics
Roelof KosteriD, Luuk J. SchipperiD, Noor A. A. GiesbertziD, Daphne M. van BeekiD, Matías MendevilleiD, Kris G. SamsomiD, Efraim H. RosenbergiD, Frans B.L. Hogervorst, Paul RoepmaniD, Mirjam C. Boelens, Linda J.W. BoschiD, José G. van den Berg, Gerrit A. MeijeriD, Emile E. VoestiD, Edwin P. J. G. CuppeniD, Mariëlle Ruijs, Tom van WezeliD, Lizet van der KolkiD, Kim MonkhorstiD
Abstract
PurposeGenome sequencing (GS) enables comprehensive molecular analysis of tumours and identification of hereditary cancer predisposition. According to guidelines, directly determining pathogenic germline variants (PGVs) requires pre-test genetic counselling, which is cost-ineffective. Referral for genetic counselling based on tumour variants alone could miss relevant PGVs and/or result in unnecessary referrals. MethodsWe validated GS for detection of germline variants and simulated three strategies using paired tumour-normal genome sequencing data of 937 metastatic patients. In strategy-1 genetic counselling prior to tumour testing allowed direct PGV analysis. In strategy-2 and -3, germline testing and referral for post-test genetic counselling is based on tumour variants using Dutch (strategy-2) or ESMO-PMWG (strategy-3) guidelines. ResultsIn strategy-1, PGVs would be detected in 50 patients (number-needed-to counsel; NTC=18.7). In strategy-2, 86 patients would have been referred for genetic counselling and 43 would have PGVs (NTC=2). In strategy-3, 94 patients would have been referred for genetic counselling and 32 would have PGVs (NTC=2.9). Hence, 43 and 62 patients, respectively, were unnecessarily referred based on a somatic variant. ConclusionBoth post-tumour test counselling strategies (2 and 3) had significantly lower NTC, and strategy-2 had the highest PGV yield. Combining pre-tumour test mainstreaming and post-tumour test counselling may maximize the clinically relevant PGV yield and minimize unnecessary referrals.
- Citations
- 9
- FWCI
- 1.49
- Field percentile
- top 17%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Germline testing data validate inferences of mutational status for variants detected from tumor-only sequencing
Nahed Jalloul, Israel Gomy, … Hossein Khiabanian·JCO Precision OncologyPeer-reviewed·Nov 1, 2021
- Genome sequencing as a generic diagnostic strategy for rare disease
Gaby Schobers, Ronny C. Derks, … Lisenka E.L.M. Vissers·medRxiv·Sep 28, 2023
- Validation of a guidelines-based digital tool to assess the need for germline cancer genetic testing
Callan D. Russell, Ashley Daley, … Colleen A. Caleshu·Hereditary Cancer in Clinical PracticePeer-reviewed·Nov 8, 2024
- BRCA-DIRECT digital pathway for diagnostic germline genetic testing within a UK breast oncology setting: a randomised, non-inferiority trial
Bethany Torr, Christopher Iain Jones, … Clare Turnbull·British Journal of CancerPeer-reviewed·Sep 30, 2024
- Molecular diagnostic yield of genome sequencing versus targeted gene panel testing in racially and ethnically diverse pediatric patients
Noura S. Abul‐Husn, Priya N. Marathe, … Bruce D. Gelb·Genetics in MedicinePeer-reviewed·May 5, 2023
- Genetic testing in cancer: a systematic review of patient reported measures
Kelsie Raspin, Daisy Nowakowski, … Jessica K. Roydhouse·medRxiv·Jul 7, 2025